Literature DB >> 9692350

The human immunodeficiency virus (HIV) epidemic and HIV-associated nephropathy.

J A Winston1, G C Burns, P E Klotman.   

Abstract

Human immunodeficiency virus (HIV)-associated nephropathy (HIVAN), the single most common cause of end-stage renal failure in seropositive patients, has increased in incidence by 30% each year since 1991. Occurring almost exclusively in blacks, HIVAN became the third leading cause of ESRD in blacks, ages 20 to 64, in 1995. During that year, the absolute number of new acquired immune deficiency syndrome (AIDS) cases declined for the first time since the epidemic began. The decrease occurred predominantly in white males, whereas in blacks with heterosexual exposures for risk factors, the incidence actually increased. Also in 1995, the number of AIDS-related deaths declined for the first time. If these trends continue, we can expect a continued increase in the number of blacks living with AIDS. We estimate that 1% to 4% will develop renal failure from HIVAN. The incidence of HIVAN can be expected to increase unless new approaches are successful in preventing the spread of HIV-1 in all segments of the population or in treating the renal complications of HIV-1 infection.

Entities:  

Mesh:

Year:  1998        PMID: 9692350

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  16 in total

1.  Race and kidney disease: the scope of the problem.

Authors:  Keith C Norris; Lawrence Y Agodoa
Journal:  J Natl Med Assoc       Date:  2002-08       Impact factor: 1.798

2.  Race, kidney disease progression, and mortality risk in HIV-infected persons.

Authors:  Tahira P Alves; Todd Hulgan; Pingsheng Wu; Timothy R Sterling; Samuel E Stinnette; Peter F Rebeiro; Andrew J Vincz; Marino Bruce; T Alp Ikizler
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-28       Impact factor: 8.237

3.  HIV-associated nephropathy in the setting of maximal virologic suppression.

Authors:  Shivaram Hegde; Cheentan Singh; Bernadette Ohare
Journal:  Pediatr Nephrol       Date:  2011-02-25       Impact factor: 3.714

4.  Urinary NGAL is a useful clinical biomarker of HIV-associated nephropathy.

Authors:  David A Sola-Del Valle; Sumit Mohan; Jen-Tse Cheng; Neal A Paragas; Meghan E Sise; Vivette D D'Agati; Jonathan Barasch
Journal:  Nephrol Dial Transplant       Date:  2011-05-09       Impact factor: 5.992

5.  Activation of Notch signaling pathway in HIV-associated nephropathy.

Authors:  Madhulika Sharma; Shannon Callen; Da Zhang; Pravin C Singhal; Gregory B Vanden Heuvel; Shilpa Buch
Journal:  AIDS       Date:  2010-09-10       Impact factor: 4.177

6.  Seasonal variation in undiagnosed HIV infection on the general medicine and trauma services of two urban hospitals.

Authors:  Kathleen A Brady; Sheila Berry; Rajan Gupta; Mark Weiner; Barbara J Turner
Journal:  J Gen Intern Med       Date:  2005-04       Impact factor: 5.128

7.  Is there a genetic basis for health disparities in human immunodeficiency virus disease?

Authors:  Cheryl Winkler
Journal:  Mt Sinai J Med       Date:  2010 Mar-Apr

8.  Human immunodeficiency virus-1 tat induces hyperproliferation and dysregulation of renal glomerular epithelial cells.

Authors:  Pier Giulio Conaldi; Antonella Bottelli; Andreina Baj; Caterina Serra; Lisa Fiore; Giovanni Federico; Benedetta Bussolati; Giovanni Camussi
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

9.  Retinoic acid utilizes CREB and USF1 in a transcriptional feed-forward loop in order to stimulate MKP1 expression in human immunodeficiency virus-infected podocytes.

Authors:  Ting-Chi Lu; Zhaohui Wang; Xiaobei Feng; Peter Chuang; Wei Fang; Yibang Chen; Susana Neves; Avi Maayan; Huabao Xiong; Yusen Liu; Ravi Iyengar; Paul E Klotman; John Cijiang He
Journal:  Mol Cell Biol       Date:  2008-07-14       Impact factor: 4.272

Review 10.  Proteinuria in paediatric patients with human immunodeficiency virus infection.

Authors:  Vania Giacomet; Paola Erba; Francesca Di Nello; Sonia Coletto; Alessandra Viganò; Gianvincenzo Zuccotti
Journal:  World J Clin Cases       Date:  2013-04-16       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.